Every material Form 8-K Globe Life filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Globe Life reported third quarter 2026 results with diluted net income of $4.62 per share, down from $4.73 a year earlier, while net operating income rose to $4.84 per share from $4.81. The company adjusted its full-year 2026 earnings guidance to $15.35 to $15.65 per share, citing high-severity claims at Evry and a Centers for Medicare and Medicaid Services claims processing delay at its United American General Agency division, and raised its 2026 share repurchase expectation to $725 million to $775 million.
Q3 2026 net income was $361.1 million, compared with $387.8 million in Q3 2025; total premium revenue rose 7% to $1.31 billion.
Health underwriting margin at United American was a loss of $6.4 million, reflecting an Evry underwriting loss of about $16 million and about $7 million of excess Medicare Supplement claims.
Full-year 2026 earnings guidance was adjusted to $15.35 to $15.65 per share; the company estimates 2027 net operating income of $16.10 to $17.10 per share.
During Q3 2026 the company repurchased 1.1 million shares for $185 million, and now expects 2026 repurchases of $725 million to $775 million, up from $670 million to $700 million.
Globe Life Inc. disclosed that director David A. Rodriguez retired from its Board of Directors effective immediately on August 4, 2026, citing personal reasons. The company said the departure was not due to any disagreement over its operations, policies or practices.
Retirement effective immediately, as of August 4, 2026
Reason given: personal reasons
Company states no disagreement with management or the board on operations, policies or practices
Disclosed in an 8-K filed August 7, 2026 under Item 5.02
Globe Life reported second quarter 2026 net income of $3.65 per diluted share, up from $3.05 a year earlier, and net operating income of $3.61 per share, up from $3.27. The company raised its full-year 2026 earnings guidance to $15.55 to $15.95 per share, an increase of $0.10 at the midpoint.
Q2 2026 net income was $3.65 per diluted share vs. $3.05 in Q2 2025, up 20%.
Q2 2026 net operating income was $3.61 per diluted share vs. $3.27, up 10%.
Full-year 2026 EPS guidance raised to $15.55 to $15.95, up $0.10 at the midpoint.
The company repurchased 1.1 million shares for $175 million during the quarter.
Globe Life signed a new $450 million term loan and a third amended credit agreement on June 26, 2026, with Wells Fargo replacing Bank of America as administrative agent. The filing shows the company extended its borrowing arrangements, with the term loan maturity moved to June 26, 2029 and the credit agreement maturity moved to June 26, 2031.
Term loan principal increased from $250 million to $450 million, with maturity extended from August 15, 2027 to June 26, 2029.
Credit agreement maturity extended from March 29, 2029 to June 26, 2031.
Wells Fargo, National Association replaces Bank of America, N.A. as administrative agent under both agreements.
The filing does not state the credit agreement's total commitment amount.
Globe Life reported first quarter 2026 net income of $3.39 per diluted share, up from $3.01 a year earlier, and net operating income of $3.43 per diluted share, up from $3.07. The company also raised its full-year 2026 earnings guidance to a range of $15.40 to $15.90, an increase of $0.35 at the midpoint.
Q1 2026 net income was $3.39 per diluted share versus $3.01 a year earlier, an increase of 13%.
Q1 2026 net operating income was $3.43 per diluted share versus $3.07, an increase of 12%.
Full-year 2026 earnings guidance was raised to $15.40 to $15.90, up $0.35 at the midpoint.
The company repurchased 1.4 million shares in the quarter for a total cost of $203 million.
Globe Life's board voted on February 25, 2026 to expand its size from twelve to fourteen directors and appointed Derek T. Kan and Sandra L. Phillips to the new seats. The filing says both will serve until the April 30, 2026 annual meeting and receive standard non-employee director compensation, which matters to shareholders mainly as a governance change rather than a financial one.
Board expanded from twelve to fourteen directors, effective February 25, 2026
Derek T. Kan appointed to the Audit Committee; Sandra L. Phillips to the Governance and Nominating Committee
Each new director gets a $110,000 prorated annual cash retainer and a $190,000 prorated annual equity retainer; Kan also receives a $12,500 Audit Committee retainer
Globe Life reported fourth quarter 2025 net operating income of $3.39 per diluted share, up from $3.14 a year earlier, and net income of $3.29 per share, up from $3.01. The company also raised its 2026 net operating income guidance to $14.95 to $15.65 per diluted share, which matters to shareholders because it signals higher expected profit for the coming year.
Q4 2025 net operating income was $3.39 per diluted share versus $3.14 a year earlier, up 8%.
Full-year 2025 net operating income was $14.52 per diluted share versus $12.37 in 2024, above the midpoint of prior guidance.
2026 net operating income guidance is $14.95 to $15.65 per diluted share, an increase from previous guidance.
Life net sales rose 11% in the quarter, and health net sales rose 71%.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Globe Life filing is on SEC EDGAR ↗. 8-K briefs of other companies →